Akebia Therapeutics (STU:AX9) FCF Margin % : -4.11% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Akebia Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was €-2.1 Mil. Akebia Therapeutics's Revenue for the three months ended in Dec. 2023 was €51.5 Mil. Therefore, Akebia Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -4.11%.

As of today, Akebia Therapeutics's current FCF Yield % is -9.22%.

The historical rank and industry rank for Akebia Therapeutics's FCF Margin % or its related term are showing as below:

STU:AX9' s FCF Margin % Range Over the Past 10 Years
Min: -119.55 Med: -34.73 Max: 3598.96
Current: -12.12

During the past 12 years, the highest FCF Margin % of Akebia Therapeutics was 3598.96%. The lowest was -119.55%. And the median was -34.73%.

STU:AX9's FCF Margin % is ranked better than
72.24% of 1041 companies
in the Biotechnology industry
Industry Median: -141.21 vs STU:AX9: -12.12

Akebia Therapeutics FCF Margin % Historical Data

The historical data trend for Akebia Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics FCF Margin % Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-78.83

-37.57

-119.55

-25.05

-12.01

Akebia Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-98.02	-43.70	6.44	-17.04	-4.11

Competitive Comparison of Akebia Therapeutics's FCF Margin %

For the Biotechnology subindustry, Akebia Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akebia Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's FCF Margin % falls into.

Akebia Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Akebia Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-21.443	/	178.469
	=	-12.01 %

Akebia Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.116	/	51.532
	=	-4.11 %

Akebia Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (STU:AX9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (STU:AX9) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AKBA:USA AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (STU:AX9) Headlines

No Headlines